Home/ Supplements/ Omega 3/ MaxEPA 1000 mg

MaxEPA 1000 mg

product on market Softgel Capsule NOW Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 33% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Fish oil concentrate provides omega-3 fatty acids, which have strong evidence for supporting cardiovascular health and managing triglyceride levels. Research indicates these ingredients contribute to the maintenance of healthy inflammatory responses. The evidence coverage for this specific profile is limited.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for MaxEPA 1000 mg
Open Full PDF View on NIH DSLD →
Details

Label Data

2 Softgel(s)
Serving Size
45
Servings
Fat/Fatty Acid
Product Type
33%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calories
20 {Calories}
Total Fat
2 g (3% DV)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)

Other Ingredients

Gelatin Glycerin
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Qualified Health
Info

Product Information

Directions for Use

SUGGESTED USAGE: As a dietary supplement, take 2 softgels 1-3 times daily with meals.

Formulation Notes

Cholesterol-Free

Natural Source of Omega-3

Contains no sugar, salt, starch, yeast, wheat, gluten, corn, milk or preservatives.

Additional Information

QUALITY ASSURED SINCE 1968

Consumption of Omega-3 fatty acids may reduce the risk of coronary heart disease. FDA evaluated the data and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive.

Made in the U.S.A.

CODE 1630 V2

ACTUAL SIZE

CAUTION: PLEASE DISCARD THE INEDIBLE FRESHNESS PACKET ENCLOSED.

Metadata

Product Details

UPC / SKU7 33739 01630 0
DSLD Entry Date2012-08-24
Product TypeFat/Fatty Acid
FormSoftgel Capsule
BrandNOW
DSLD ID12702
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.